Integrated Safety Profile of a New Approved, Fully Liquid DTaP5-HB-IPV-Hib Vaccine.

Authors:
Jin Xu
Jin Xu
Fudan University Shanghai Cancer Center
China
Jon E Stek
Jon E Stek
University of Puerto Rico School of Medicine
Eddy Ziani
Eddy Ziani
Sanofi Pasteur MSD
Andrew W Lee
Andrew W Lee
Stanford University School of Medicine
United States

Pediatr Infect Dis J 2019 Apr;38(4):439-443

From the Merck & Co., Inc., Kenilworth, NJ.

Background: DTaP5-HB-IPV-Hib is a fully liquid, hexavalent vaccine containing a 5-antigen pertussis component, approved since 2016 in Europe [Vaxelis; DTaP5-HB-IPV-Hib vaccine: Diphtheria, tetanus, pertussis (5 acellular components: pertussis toxoid [PT], filamentous haemagglutinin [FHA], pertactin (PRN), and fimbriae Types 2 and 3 [FIM]), hepatitis B (recombinant DNA: rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type b conjugate vaccine (adsorbed); MCM Vaccine B.V., The Netherlands] for primary and booster vaccination in infants and toddlers against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by Haemophilus influenzae type b. The comparator vaccine (control) was INFANRIX hexa (GlaxoSmithKline Biologics S.A., Rixensart, Belgium) (DTaP3-IPV-HepB/Hib) in European studies and PENTACEL (DTaP5-IPV/Hib) (Sanofi Pasteur, Swiftwater, PA) in US studies.

Methods: Data from 6 studies were integrated and analyzed to provide a comprehensive safety profile. Numbers and proportions of subjects with adverse events (AEs) were summarized by treatment group. Group differences in proportion of AEs were calculated.

Results: Among the DTaP5-HB-IPV-Hib (N = 5223) and 2295 control (N = 2295) groups, solicited injection-site and systemic AEs were very common. Serious AEs were reported by 3.9% of DTaP5-HB-IPV-Hib and 3.7% of control subjects. Vaccine-related serious AEs occurred infrequently, 0.2% for both groups. Most AEs were mild-to-moderate and did not lead to subject withdrawal. Group differences for solicited systemic AEs were small (<3%) and not statistically significant, except for pyrexia (estimated difference 9.4% [95% CI: 6.7%-12%]). The difference was driven by the 2 US studies where the PENTACEL control group had a lower fever rate. Among European studies, there was no significant difference in rates of pyrexia between DTaP5-HB-IPV-Hib and INFANRIX hexa.

Conclusions: The safety of DTaP5-HB-IPV-Hib is consistent with the safety profile of its components and similar to comparator vaccines, including INFANRIX hexa. The vaccine provides a new, fully liquid and convenient hexavalent vaccination option for use with various vaccination schedules in Europe.

Download full-text PDF

Source
http://dx.doi.org/10.1097/INF.0000000000002257DOI Listing
April 2019
3 Reads

Publication Analysis

Top Keywords

dtap5-hb-ipv-hib vaccine
8
tetanus pertussis
8
systemic aes
8
influenzae type
8
haemophilus influenzae
8
diphtheria tetanus
8
group differences
8
fully liquid
8
safety profile
8
serious aes
8
aes
7
vaccine
6
dtap5-hb-ipv-hib
5
pentacel dtap5-ipv/hib
4
european studies
4
swiftwater studiesmethods
4
studies pentacel
4
sanofi pasteur
4
dtap5-ipv/hib sanofi
4
pasteur swiftwater
4

Similar Publications